Eleven Month Progression-Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E-Mutated Glioblastoma WHO Grade 4

JCO Precis Oncol. 2017 Nov:1:1-5. doi: 10.1200/PO.17.00055.
No abstract available